Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod and Cemiplimab in Advanced or Metastatic Cancer
NCT04916002Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of vidutolimod in cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC), triple-negative breast cancer (TNBC), basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
vidutolimod
03
Conditions
cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)triple-negative breast cancer (TNBC)basal cell carcinoma (BCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04916002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916002.